This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ebert, L. M. Articles by Chen, W. Search for Related Content PubMed PubMed Citation Articles by Ebert, L. M. Articles by Chen, W.

The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells

¹ Ludwig Institute for Cancer Research (Melbourne Center for Clinical Sciences) and ² Department of Pathology, Austin Health, Heidelberg, Victoria, Australia and ³ Epstein-Barr Virus Laboratory, Queensland Institute of Medical Research, Herston, Queensland, Australia

Requests for reprints: Weisan Chen or Lisa Ebert, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia. Phone: 61-3-9496-3700; Fax: 61-3-9457-6698; E-mail: weisan.chen{at}ludwig.edu.au or lisa.ebert{at}ludwig.edu.au.

Key Words: FoxP3 • regulatory T cell • melanoma • tumor cell • immune suppression

FoxP3 is a member of the forkhead family of transcription factors critically involved in the development and function of CD25⁺ regulatory T cells (Treg). Until recently, FoxP3 expression was thought to be restricted to the T-cell lineage. However, using immunohistochemistry and flow cytometric analysis of human melanoma tissue, we detected FoxP3 expression not only in the tumor infiltrating Treg but also in the melanoma cells themselves. FoxP3 is also widely expressed by established human melanoma cell lines (as determined by flow cytometry, PCR, and Western blot), as well as cell lines derived from other solid tumors. Normal B cells do not express FoxP3; however, expression could be induced after transformation with EBV in vitro and in vivo, suggesting that malignant transformation of healthy cells can induce FoxP3. In addition, a FOXP3 mRNA variant lacking exons 3 and 4 was identified in tumor cell lines but was absent from Treg. Interestingly, this alternative splicing event introduces a translation frame-shift that is predicted to encode a novel protein. Together, our results show that FoxP3, a key regulator of immune suppression, is not only expressed by Treg but also by melanoma cells, EBV-transformed B cells, and a wide variety of tumor cell lines. [Cancer Res 2008;68(8):3001–9]

This article has been cited by other articles:

				H. Lu FOXP3 Expression and Prognosis: Role of Both the Tumor and T Cells J. Clin. Oncol., April 10, 2009; 27(11): 1735 - 1736. [Full Text] [PDF]

				T. Nicholaou, L. M. Ebert, I. D. Davis, G. A. McArthur, H. Jackson, N. Dimopoulos, B. Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, et al. Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma Clin. Cancer Res., March 15, 2009; 15(6): 2166 - 2173. [Abstract] [Full Text] [PDF]